Trial intelligence / Profile preview

Asciminib with low-intensity chemotherapy followed by asciminib with blinatumomab in relapsed or refractory Ph+ or ABL-class Ph-like B-cell acute lymphoblastic leukemia

MOH_2026-02-15_015659Phase 2Recruiting

Sponsor

Novartis

Start

Feb 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1